On top of that, suppressed GLP‐1R and GIPR expression in human T2D islets as revealed by the current and other studies (Lyssenko et al, 2011; Taneera et al, 2012; Guo et al, 2013) is expected to lead directly to incretin resistance and lower the efficacy of treatments. The gene discussed is GIPR; the disease is type 2 diabetes mellitus.